Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment symbols : Chrs save search
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
Published: 2023-12-11 (Crawled : 13:30) - globenewswire.com
CHRS | $1.995 -0.25% 1.4M
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -5.38%
guidelines cancer treatment
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association
Published: 2023-11-28 (Crawled : 16:00) - globenewswire.com
CHRS | $1.995 -0.25% 1.4M
|
Health Technology
|
| O: -1.55%
H: 12.83%
C: 10.47%
piter-02 association positive publication treatment medical trial results
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Published: 2023-10-27 (Crawled : 19:00) - globenewswire.com
CHRS | $1.995 -0.25% 1.4M
|
Health Technology
| Email alert
Add to watchlist
SURF | $1.07 -0.93% -1.41% 0
|
Health Technology
| Email alert
Add to watchlist
fda approval treatment
Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
Published: 2023-02-15 (Crawled : 15:00) - biospace.com/
CHRS | $1.995 -0.25% 1.4M
|
Health Technology
|
| O: 0.13%
H: 0.63%
C: -1.13%
piter-02 treatment trial positive
Junshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
Published: 2023-02-15 (Crawled : 15:00) - globenewswire.com
CHRS | $1.995 -0.25% 1.4M
|
Health Technology
|
| O: 0.13%
H: 0.63%
C: -1.13%
piter-02 treatment trial positive
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Published: 2022-12-25 (Crawled : 16:20) - globenewswire.com
CHRS | $1.995 -0.25% 1.4M
|
Health Technology
| Email alert
Add to watchlist
treatment fda application license review update
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Published: 2022-12-24 (Crawled : 08:20) - globenewswire.com
CHRS | $1.995 -0.25% 1.4M
|
Health Technology
| Email alert
Add to watchlist
treatment fda application license review update
Junshi Biosciences and Coherus Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology
Published: 2022-10-12 (Crawled : 13:00) - globenewswire.com
CHRS | $1.995 -0.25% 1.4M
|
Health Technology
|
| O: -1.15%
H: 1.63%
C: -0.93%
hoice-01 treatment lung trial positive publication
Junshi Biosciences and Coherus Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
Published: 2022-07-06 (Crawled : 13:00) - biospace.com/
CHRS | $1.995 -0.25% 1.4M
|
Health Technology
|
| O: 0.12%
H: 5.85%
C: 3.86%
treatment fda resubmission
Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
Published: 2022-07-06 (Crawled : 13:00) - biospace.com/
CHRS | $1.995 -0.25% 1.4M
|
Health Technology
|
| O: 0.12%
H: 5.85%
C: 3.86%
treatment fda resubmission
Junshi Biosciences and Coherus Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
Published: 2022-04-09 (Crawled : 04:20) - globenewswire.com
CHRS | $1.995 -0.25% 1.4M
|
Health Technology
| Email alert
Add to watchlist
treatment results phase 3
Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
Published: 2022-04-08 (Crawled : 18:00) - globenewswire.com
CHRS | $1.995 -0.25% 1.4M
|
Health Technology
|
| O: -0.4%
H: 3.36%
C: -0.08%
treatment results phase 3
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series
Published: 2022-03-15 (Crawled : 13:30) - globenewswire.com
CHRS | $1.995 -0.25% 1.4M
|
Health Technology
|
| O: 1.41%
H: 5.81%
C: 2.53%
hoice-01 treatment pos trial presentation cel positive results asco lung cancer positive therapy bioscience results cancer phase 3
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
CHRS | $1.995 -0.25% 1.4M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
hoice-01 treatment trial lung cancer positive therapy bioscience results cancer phase 3
Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
Published: 2021-11-01 (Crawled : 12:15) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 2.72%
H: 0.41%
C: -0.38%
CHRS | $1.995 -0.25% 1.4M
|
Health Technology
|
| O: 1.49%
H: 3.83%
C: 0.0%
treatment fda fda acceptance
Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal CarcinomaFDA has granted the toripalimab BLA Priority Review with a target action date of April 2022
Published: 2021-11-01 (Crawled : 12:15) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 2.72%
H: 0.41%
C: -0.38%
CHRS | $1.995 -0.25% 1.4M
|
Health Technology
|
| O: 1.49%
H: 3.83%
C: 0.0%
treatment fda fda acceptance granted
Junshi Biosciences and Coherus to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
Published: 2021-09-17 (Crawled : 01:00) - globenewswire.com
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
CHRS | $1.995 -0.25% 1.4M
|
Health Technology
|
| O: 1.12%
H: 0.0%
C: 0.0%
treatment positive therapy results phase 3 trial cell carcinoma
Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
Published: 2021-09-16 (Crawled : 23:00) - globenewswire.com
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
CHRS | $1.995 -0.25% 1.4M
|
Health Technology
|
| O: 1.12%
H: 0.0%
C: 0.0%
treatment positive therapy results phase 3 trial cell carcinoma
Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
Published: 2021-09-14 (Crawled : 02:00) - globenewswire.com
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 0.47%
H: 0.07%
C: -1.4%
CHRS | $1.995 -0.25% 1.4M
|
Health Technology
|
| O: 0.31%
H: 0.49%
C: -0.86%
treatment lung cancer positive results cancer conference
Positive Interim Results of CHOICE-01 Study Evaluating Junshi Biosciences and Coherus’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
Published: 2021-09-14 (Crawled : 02:00) - globenewswire.com
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 0.47%
H: 0.07%
C: -1.4%
CHRS | $1.995 -0.25% 1.4M
|
Health Technology
|
| O: 0.31%
H: 0.49%
C: -0.86%
treatment lung cancer positive results cancer conference
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.054 50.0% 290M
|
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
RWOD | $10.08 26.05% 5.6M
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
TPET | $0.4001 22.02% 35M
|
n/a
SRFM 4 | $0.6 21.29% 850K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.